{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"4"}]}],"title":"DBP, any grade increase"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"7"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"5"}]}],"title":"SBP, any grade increase"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"6"}],"units":"Participants"}],"description":"Vital signs included systolic blood pressure (SBP), diastolic blood pressure (DBP), temperature (Temp) and heart rate (HR). SBP and DBP were graded using National Cancer Institute-Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0. For SBP: Grade 0-\\<120 millimeters of mercury\\[mmHg\\], 120-139 mmHg\\[Grade 1\\], 140-159 mmHg\\[Grade 2\\], \\>=160 mmHg\\[Grade 3\\]); For DBP: \\<80 mmHg \\[Grade 0\\], 80-89\\[Grade 1\\], 90-99\\[Grade 2\\], \\>=100 mmHg\\[Grade 3\\]). An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was defined as the latest pre-dose assessment with a non-missing value, including unscheduled visits. Data for worst-case post Baseline is presented.","groups":[{"description":"Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG000","title":"Part 1: GSK2857916 0.03 mg/kg"},{"description":"Participants were administered a dose of 0.06 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG001","title":"Part 1: GSK2857916 0.06 mg/kg"},{"description":"Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG002","title":"Part 1: GSK2857916 0.12 mg/kg"},{"description":"Participants were administered a dose of 0.24 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG003","title":"Part 1: GSK2857916 0.24 mg/kg"},{"description":"Participants were administered a dose of 0.48 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG004","title":"Part 1: GSK2857916 0.48 mg/kg"},{"description":"Participants were administered a dose of 0.96 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG005","title":"Part 1: GSK2857916 0.96 mg/kg"},{"description":"Participants were administered a dose of 1.92 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG006","title":"Part 1: GSK2857916 1.92 mg/kg"},{"description":"Participants were administered a dose of 2.50 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG007","title":"Part 1: GSK2857916 2.50 mg/kg"},{"description":"Participants were administered a dose of 3.40 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG008","title":"Part 1: GSK2857916 3.40 mg/kg"},{"description":"Participants were administered a dose of 4.60 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG009","title":"Part 1: GSK2857916 4.60 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Part 1 Population","reportingStatus":"POSTED","timeFrame":"Baseline and Up to 21.6 months (maximum duration of follow-up from first dose to last contact or death)","title":"Number of Participants With Grade Change From Baseline in Vital Signs-DBP & SBP-Part 1","type":"PRIMARY","unitOfMeasure":"Participants"}